Q BioMed Cash Flow Statement

Financials in millions USD. Fiscal year is December - November.

Millions USD. Fiscal year is Dec - Nov.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Feb '23 Feb 28, 2023	Nov '22 Nov 30, 2022	Nov '21 Nov 30, 2021	Nov '20 Nov 30, 2020	Nov '19 Nov 30, 2019	Nov '18 Nov 30, 2018
Net Income	-0.49	-2.05	-8.24	-13.49	-10.28	-9.27
Depreciation & Amortization	0.05	0.05	0.05	0.05	0.05	-
Other Amortization	0.77	0.92	0.41	0.14	1	0.13
Stock-Based Compensation	0.77	0.9	2.34	6.57	2.5	2.65
Other Operating Activities	-0.36	0.37	0.35	0.18	0.93	0.09
Change in Accounts Receivable	0.03	0.07	-0.08	-0.09	-	-
Change in Accounts Payable	1.19	1.47	0.84	0.57	1.41	-0.07
Change in Other Net Operating Assets	0.23	0.21	0.04	-0.16	0.29	0.02
Operating Cash Flow	2.18	1.94	-4.3	-6.23	-4.11	-6.45
Sale (Purchase) of Intangibles	-	-	-	-	-	-0.5
Investment in Securities	-3.14	-3.14	-	-	-	-
Investing Cash Flow	-3.14	-3.14	-	-	-	-0.5
Short-Term Debt Issued	-	0.65	3.49	1.97	-	-
Long-Term Debt Issued	-	-	-	-	0.97	3.87
Total Debt Issued	0.76	0.65	3.49	1.97	0.97	3.87
Short-Term Debt Repaid	-	-	-0.03	-	-	-
Total Debt Repaid	-	-	-0.03	-	-	-
Net Debt Issued (Repaid)	0.76	0.65	3.46	1.97	0.97	3.87
Issuance of Common Stock	-	0.1	1.01	0.32	0.62	4.95
Other Financing Activities	0.09	0.16	-	-	-	-
Financing Cash Flow	0.85	0.91	4.47	6.24	1.59	8.81
Net Cash Flow	-0.38	-0.29	0.17	0	-2.51	1.86
Cash Interest Paid	-	-	0	-	0.03	-
Levered Free Cash Flow	1.96	0.53	-1.37	-2.05	-0.82	-3.51
Unlevered Free Cash Flow	1.97	0.47	-1.46	-2.01	-0.91	-3.54
Change in Working Capital	1.44	1.75	0.8	0.32	1.7	-0.05

Updated Jun 16, 2023. Source: S&P Global Market Intelligence. Standard template. Financial Sources.